Corporate Overview
On this page:
Baxter International Inc. (NYSE:BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter had 2009 sales of $12.6 billion and has approximately 49,700 employees.
Business Overview
BioScience
2009 Sales-$5.6 Billion
Baxter is a leading manufacturer of recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and vaccines.
Medication Delivery
2009 Sales-$4.65 Billion
Baxter is a leading manufacturer of products used in the delivery of fluids and drugs to patients. These include intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics, as well as products and services related to pharmacy compounding, drug formulation and packaging technologies.
Renal
2009 Sales-$2.3 Billion
Baxter's Renal business provides products to treat end-stage renal disease, or irreversible kidney failure. The business manufactures solutions and other products for peritoneal dialysis (PD), a home-based therapy, and also distributes products for hemodialysis (HD), which is generally conducted in a hospital or clinic.
2009 Sales by Business
2009 Sales by Region
Regional Employee Breakdown
| 2007 | 2008 | 2009 | ||
| United States | 19,600 | 20,600 | 20,600 | |
| Europe | 13,500 | 14,200 | 14,700 | |
| Latin America | 5,900 | 5,900 | 6,100 | |
| Asia Pacific | 6,200 | 6,600 | 7,100 | |
| Canada | 1,125 | 1,150 | 1,150 | |
| Total | 46,325 | 48,450 | 49,700 |
R&D; Expenditures (in millions)
Because of our commitment to research and development, Baxter’s history is rich with medical firsts, from the first commercially manufactured intravenous (IV) solutions to the first portable kidney dialysis machine, plus many more. Baxter continually pursues breakthrough technologies through research facilities around the world, and our investments reflect that commitment.
